CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Olanzapine +3 moredrug
Likely dose
Olanzapine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02484911
NCT02484911Phase 3Completed
CompareCT.gov

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial

First Affiliated Hospital of Harbin Medical University·interventional·Posted Jun 30, 2015·Updated Mar 30, 2017

In Brief

A Phase 3 clinical trial evaluating Olanzapine, Aprepitant, and 2 other interventions for Chemotherapy-induced Nausea and Vomiting. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Nausea and Vomiting
CountriesChina
CollaboratorsHarbin Medical University

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 30, 2015
Enrollment StartMay 1, 2015
Primary CompletionSep 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.0 years ago

Interventions

Olanzapinedrug

5mg,twice a day orally on day 1 to day 4

Aprepitantdrug

125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.

Palonosetrondrug

0.25mg IV 30-60min before chemotherapy on day 1

Dexamethasonedrug

6mg IV on day 1 ，3.75mg IV on day 2 to 4